Sellas Life Sciences expands SAB with Philip Amrein, Alex Kentsis

SELLAS Life Sciences (SLS) Group announced the appointment of two oncology leaders to its Scientific Advisory Board. The new members – Philip Amrein, MD, and Alex Kentsis, MD, PhD bring decades of expertise in cancer research, clinical oncology, and translational medicine, further strengthening the company’s strategic guidance as it advances its therapeutic pipeline. Amrein is an Assistant Professor of Medicine at Harvard Medical School and a physician at the MGH, where he specializes in leukemia. He is part of the Cancer Center, Leukemia, Cellular Immunotherapy, and Hematology/Oncology departments. Dr. Kentsis is the founding Director of the MSK Tow Center for Developmental Oncology, a practicing pediatric oncologist at MSK Kids, a Member of the Sloan Kettering Institute, and Professor of Pediatrics, Pharmacology, and Physiology & Biophysics at Weill Cornell Medical College of Cornell University.